🧬 Aging Wiki

uv-protection

Properties1
aliasessunscreen, sun protection, photoprotection, broad-spectrum UV protection, UV avoidance

23 min read

UV protection (sunscreen + photoprotection)

Daily broad-spectrum UV protection — encompassing topical sunscreen, protective clothing, shade-seeking behavior, and UV-protective eyewear — is the single best-evidenced anti-photoaging intervention available 1. The evidence base rests on a 4.5-year RCT in 903 adults demonstrating 24% less skin aging in daily vs. discretionary sunscreen users 2, mechanistic work establishing that even sub-erythemogenic UV doses (0.01 MED threshold) activate the AP-1/NF-κB → MMP-1/3/9 cascade within minutes 3, and decades of converging observational and experimental data. Unlike pharmacological anti-aging interventions, UV protection has a firmly implemented, FDA-regulated OTC framework, makes minimal physiological demands, and poses no systemic risk at standard use.

This page covers UV protection as a lifestyle intervention portfolio (sunscreen + behavioral + clothing). For retinoids used alongside sunscreen, see retinoids. For antioxidant adjuncts (vitamin C/E/ferulic acid), see ascorbic-acid and alpha-tocopherol.

UV biology (brief — cross-link)

Solar UV radiation reaches the skin in two biologically active bands:

BandWavelengthDepth of penetrationPrimary damage
UVB290–320 nmEpidermis (~100% absorbed)CPDs + 6–4PPs (direct DNA photoproducts); p53 activation; AP-1/NF-κB → MMP cascade
UVA-II320–340 nmUpper dermisROS-mediated indirect DNA damage; pigmentation
UVA-I340–400 nmDeep dermisROS; collagen cross-linking; immunosuppression; pigmentation

The mechanistic anchor is Fisher 1996 3: in human buttock skin, UVB at 0.01 MED (sub-erythemogenic) activates AP-1 and NF-κB within minutes. Downstream AP-1 drives transcription of MMP-1 (interstitial collagenase), MMP-3 (stromelysin-I), and MMP-9 (gelatinase B) — the triad that degrades dermal collagen-I and collagen-III, elastin, and fibronectin. This is the proximate molecular mechanism of photoaging. Chronic repetitive activation at everyday UV exposures (window glass transmits UVA-I but not UVB; indirect skylight carries UV even in shade) produces cumulative photoaged dermis.

The full exposome picture from Krutmann 2017 1 identifies UV as the dominant extrinsic driver but additionally implicates visible light (400–700 nm; pigmentation via melanocortin), infrared-A (IRA; mitochondrial ROS), air pollution (PM-induced oxidative stress → MMP induction), and tobacco smoke (independent MMP induction). These factors interact non-additively. Full-spectrum protection against UV + visible light is the current frontier.

Sunscreen types

Mineral (inorganic) filters

Zinc oxide (ZnO) provides broad-spectrum UVB + UVA-I + UVA-II coverage. High photostability; well-tolerated by sensitive skin; no systemic endocrine activity detected at standard topical doses. Can leave visible white cast at high concentrations, though nano- and micronized formulations reduce this.

Titanium dioxide (TiO₂) primarily absorbs UVB and UVA-II; less UVA-I coverage than zinc oxide. Also highly photostable. Often combined with zinc oxide for broader spectrum.

Tinted mineral formulations incorporate iron oxides (ferric oxide pigments) that extend protection into the visible light range (400–700 nm), relevant for melasma and post-inflammatory hyperpigmentation and potentially for photoaging driven by VL/IRA 4. The Krutmann 2021 review 5 advocates for iron-oxide-containing formulations as the next step in comprehensive daily photoprotection. needs-replication — direct RCT evidence that adding iron oxide to sunscreen reduces photoaging endpoints (beyond pigmentation) in otherwise healthy skin has not been published as of 2026.

Chemical (organic) filters

UVA-I filters: avobenzone (butyl methoxydibenzoylmethane) is the principal UVA-I absorber approved in the US. Photolabile in isolation; requires photostabilizers (octocrylene, ensulizole) or is encapsulated/microencapsulated in advanced formulations. Tinosorb S (bis-ethylhexyloxyphenol methoxyphenyl triazine; bemotrizinol) is a broad-spectrum photostable UVB+UVA filter approved in EU, Asia, and Australia but not yet FDA-cleared for OTC use in the US; considered one of the best single-molecule broad-spectrum filters available.

UVA-II + UVB filters: oxybenzone (benzophenone-3) — UVB + UVA-II; effective and photostable but subject to growing regulatory scrutiny for aquatic ecotoxicity (reef bleaching, banned in Hawaii and parts of Florida). Octinoxate (ethylhexyl methoxycinnamate) — widely used UVB filter, low irritation, poor UVA coverage; also subject to reef-concern regulation.

Advanced EU/Asia filters offering broader coverage: tinosorb M (methylene bis-benzotriazolyl tetramethylbutylphenol), ecamsule (Mexoryl SX, terephthalylidene dicamphor sulfonic acid), drometrizole trisiloxane (Mexoryl XL), iscotrizinol (HDT) — broader UVA+UVB profile, superior photostability, but not FDA-approved for OTC use in the US as of 2026 (FDA 2019 GRASE rule deferred most new organic filters pending additional safety data).

Ultra-long UVA-I filters (380–400 nm “UV-blue gap”): Conventional UVA-I filters drop off above ~370 nm — avobenzone λmax 357, Tinosorb S 343, Uvinul A Plus 354, Mexoryl SX 345. The 380–400 nm tail of the UVA band still penetrates to the deep dermis and drives ROS-mediated photoaging, pigmentation, and immunosuppression. Two filters launched after 2018 specifically target this band:

  • Mexoryl 400 / MCE (mexoryl-400): methoxypropylamino cyclohexenylidene ethoxyethylcyanoacetate (PubChem CID 71226339; CAS 1419401-88-9; MW 322.4 Da; λmax 385 nm). EU SCCS S87 (Dec 2019); authorized ≤3% in Annex VI by Commission Regulation (EU) 2020/1684 (Nov 2020). Australia TGA-permitted. Canada-approved. Not FDA-GRASE. The differentiating filter in the La Roche-Posay Anthelios UVMune 400 line. Human evidence: three L’Oréal-authored intra-individual hemiface/hemibody RCTs (Marionnet 2022 n=19 lab challenge 6; Flament 2024 n=113 outdoor 8 wk 7; Mercurio 2025 n=52 outdoor 4 wk 8) showed MCE-side superiority on pigmentation chromametry + clinical-grader aging signs vs the same SPF 50+ base minus MCE. No independent efficacy replication. First-published independent adverse-event signal: Loretan 2024 case report of allergic contact dermatitis 9. no-independent-replication

  • TriAsorB / PBT (triasorb): phenylene bis-diphenyltriazine (PubChem CID 59516799; CAS 55514-22-2; MW 540.6 Da; built on a 1,2,4-triazine scaffold, NOT the s-triazine of Tinosorb S/M). EU SCCS S86 (Jul 2018); authorized ≤5% by Commission Regulation (EU) 2019/680 (Apr 2019). Australia TGA-permitted. NOT on Canadian Sunscreen Monograph; not FDA-GRASE. Operates as a hybrid absorber + reflector: covers UVB through HEV (visible blue 400–450 nm), with measurable HEV reflectance beyond pure absorption. The differentiating filter in Pierre Fabre’s Avène Sunsimed and Intense Protect lines. Human evidence: Boyer 2023 (two hemi-back intra-individual studies, n=20+16, 412 nm 50 J/cm² challenge) reported 50.7–75.5% reduction in BL-induced immediate pigmentation by colorimetry 10; Le Digabel 2023 in-vivo multispectral reflectance favoring TriAsorB product over 5 SPF50+ comparators 11. No independent efficacy replication. Environmental concern: Fagervold 2025 showed TriAsorB resists biodegradation in marine sediment microcosms after 100 d 12. no-independent-replication

MCE vs PBT — what each adds. MCE has the cleaner 385 nm λmax and the deepest UVA-I tail; PBT has the broader spectrum (covers UVB+UVA+HEV) and intrinsic HEV reflectance, meaning TriAsorB-containing formulas can absorb visible-light without requiring iron-oxide pigments (though pigments may still be added for cosmetic uniformity). Neither has independent efficacy data, neither is US-available, neither has long-term outdoor photoaging endpoints with histology. For melasma / post-inflammatory hyperpigmentation, PBT chemistry + iron-oxide pigments are the most complete visible-light coverage available. For deep UVA-I gap-filling without visible-light claims, MCE is the more focused tool.

US regulatory context: Only 16 UV filter ingredients are generally recognized as safe and effective (GRASE) by FDA. FDA’s 2019 proposed rulemaking found only zinc oxide and titanium dioxide as GRASE Category I; most organic filters remain Category III (insufficient data) pending long-term systemic-exposure studies.

Chemical filter systemic absorption

The FDA’s regulatory caution toward chemical filters is grounded in two pharmacokinetic studies from the FDA’s own Office of Clinical Pharmacology demonstrating that under maximal-use conditions (2 mg/cm² × 4 applications/day × 4 days, on 75% of body surface area), all tested chemical filters cross the 0.5 ng/mL plasma threshold above which long-term systemic safety has not been established:

FilterCmax (Matta 2019/2020 maximal-use)
Oxybenzone (benzophenone-3)Up to 209.6 ng/mL 13
Avobenzone4.0–8.7 ng/mL (lotion → spray) 13
Octocrylene4.5–7.8 ng/mL 13
Ecamsule (Mexoryl SX)1.5 ng/mL 13
HomosalateUp to 23.1 ng/mL 14
OctisalateUp to 5.1 ng/mL 14
OctinoxateUp to 7.9 ng/mL 14

Matta 2020 further documented plasma persistence through day 21 post-application for several filters. Critically, the 0.5 ng/mL threshold is a regulatory trigger for additional safety testing, NOT an established harm threshold — no clinical endocrine, reproductive, or carcinogenic harm has been demonstrated at these exposures. In-vitro estrogenic signal exists for oxybenzone, octinoxate, and homosalate at concentrations above what dermal absorption produces; avobenzone, octisalate, and the high-MW EU filters (Tinosorb S MW 627, Mexoryl SX MW 562, Mexoryl XL MW 501, PBT MW 540, MCE MW 322) show the weakest endocrine signals on the panel. long-term-unknown

Practical filter-stack risk ranking (relative concern under daily-use conditions, based on Cmax + endocrine signal + ecotoxicity):

  1. Mineral only (ZnO ± TiO₂) — no systemic absorption; pregnancy + sensitive-skin default
  2. EU-grade non-avobenzone organic stack (Tinosorb S/M + Mexoryl SX/XL + Uvinul A Plus + MCE or PBT) — high-MW filters, negligible plasma absorption in published work
  3. EU-grade stack including avobenzone (UVMune 400 layout: avobenzone + Tinosorb S + Mexoryl SX/XL + MCE + co-filters) — avobenzone is the only systemically-absorbed filter; 4–8.7 ng/mL Cmax with no demonstrated harm but long-term-unknown
  4. US-grade organic stack (avobenzone + homosalate + octisalate + octocrylene, typical US Anthelios formula) — three additional systemically-absorbed filters including homosalate
  5. Legacy chemical stacks with oxybenzone / octinoxate — strongest endocrine signal + ecotoxicity (reef-bleaching restrictions); avoid

This ranking is conservative — the photoaging-prevention benefit of any sunscreen is demonstrated (Hughes 2013 OR 0.76 over 4.5 yr), the systemic-absorption harm is unquantified. Declining sunscreen entirely is worse than any of the above choices. The ranking is most useful when choosing among effective sunscreens with comparable application compliance.

SPF and UVA ratings

SPF (Sun Protection Factor) measures UVB protection via the ratio of the UV dose required to produce minimal erythema on protected vs. unprotected skin:

SPFUVB blockedTransmitted UVB
1593.3%6.7%
3096.7%3.3%
5098.0%2.0%
10099.0%1.0%

Returns are diminishing above SPF 50; SPF 30 is typically sufficient for regular daily use (residual UVB transmission difference SPF 30 vs 50 = 0.7 percentage points). SPF 50+ is warranted for prolonged outdoor exposure or high-altitude/tropical settings.

UVA ratings: The FDA “broad spectrum” label requires a Critical Wavelength ≥370 nm (i.e., some UVA-I absorption). The EU uses the UVA Protection Factor (UVA-PF; minimum 1/3 of SPF) and the black star Boots rating. Japan and Asia use the PA system (PA+ to PA++++, reflecting PPD — persistent pigment darkening — factor). A 4-star PA++++ corresponds to PPD ≥16. For anti-photoaging purposes, UVA-PF ≥10–12 is desirable (analogous to SPF ≥30 for UVA).

Clinical evidence

Hughes 2013 — the primary photoaging RCT

The strongest direct evidence for sunscreen as a photoaging intervention comes from Hughes et al. 2013 (Annals of Internal Medicine), a 4.5-year randomized trial in 903 Australian adults ≤55 years of age at enrollment (mean age 39 years; conducted in Queensland, Australia, 1992–1996) 2. The trial used a 2×2 factorial design with four arms: daily SPF 15+ broad-spectrum sunscreen + beta-carotene; daily sunscreen + placebo; discretionary sunscreen use + beta-carotene; and discretionary sunscreen use + placebo. The sunscreen comparison (daily vs. discretionary use) was the primary photoaging arm. Primary outcome was skin microtopography of dermal elastosis on the dorsal hands (silicone cast + optical profilometry). Result: visible skin aging was 24% less in the daily sunscreen group vs discretionary users (relative odds 0.76; 95% CI 0.59–0.98). Beta-carotene supplementation showed no overall benefit for photoaging. Randomized; controlled; community-based sample; 4.5 years is the longest photoaging RCT in the literature.

Limitations: The study was conducted with a broad-spectrum SPF 16 sunscreen with low UVA protection (per Krutmann 2021’s characterization; more recent sunscreens with better UVA protection may be expected to be even more effective); the “discretionary use” control group was typically recreational use only; Australian ambient UV levels are higher than mid-latitude Northern Hemisphere exposure, potentially limiting generalizability. No matched data on clothing/shade use. The beta-carotene arm showed no benefit and is not part of the photoaging-intervention evidence. long-term-unknown — Hughes 2013 is 4.5 years; 10-year, 20-year, or lifetime-cumulative effects have not been studied in a controlled design (ethical infeasibility).

Rönsch 2021 systematic review — controlled trials

A systematic review of controlled and randomized controlled trials evaluating sunscreen effectiveness (5 trials, 28–1,621 participants) found significant beneficial effects on actinic keratosis (all 4 evaluating studies), significant reduction of squamous cell carcinoma (2 studies), and significant reduction of photoaging (within-cohort), with non-significant basal cell carcinoma trends 15. Supports the RCT finding but notes the relatively small number of adequately powered trials.

Krutmann 2021 — daily photoprotection review

An authoritative 2021 review by Krutmann et al. 5 (Krutmann J, Schalka S, Watson REB, Wei L, Morita A; Photodermatol Photoimmunol Photomed; FWCI 17.1; 78 citations as of archive record) argues that modern photoprotection must extend beyond UV to include visible light and short IRA, that antioxidant-containing sunscreen formulations provide additional benefits against IRA and pollution-induced oxidative stress, and that iron-oxide-pigmented (tinted) sunscreens add visible-light protection relevant to melasma prevention and actinic lentigo. The review recommends SPF ≥30 with high UVA-PF as the baseline, supplemented with antioxidant and anti-aging active ingredients. Notably, the review states that sunscreen is generally under-applied at only 25% of the recommended dose in real-world use. This framing — Krutmann 2017 exposome → Krutmann 2021 expanded-spectrum protection recommendation — is the current field standard.

Photolyase-containing sunscreens

A 2022 RCT (Alvares; n=40 participants, 80 forearms, factorial design) compared photolyase-enriched sunscreen vs. standard sunscreen in patients aged 60–90 years with existing photodamage + actinic keratoses 16. Both sunscreens were SPF 99. Topical antioxidants (15% L-ascorbic acid + 1% alpha-tocopherol + 0.5% ferulic acid, applied as a nocturnal adjunct; n=38 forearms) significantly reduced actinic keratosis count vs. placebo (22% reduction, p<0.05); partial clearance was achieved in 47.4% of AOx forearms vs. 23.7% of placebo forearms (p=0.018). No significant difference was found between photolyase-containing and regular sunscreen formulations on any primary or secondary outcome. A 2020 systematic review 17 of DNA repair enzymes in sunscreens (52 relevant studies from 352 identified; Luze H, Nischwitz SP, Zalaudek I, Müllegger R, Kamolz LP) concluded: “There is a lack of randomized controlled trials demonstrating the efficacy of DNA repair enzymes on photoageing, or a superiority of sunscreens with DNA repair enzymes compared to conventional sunscreens.” Supports standard filters over enzyme-enriched formulas for primary photoaging prevention; data for prevention (not reversal) are even thinner.

Behavioral UV avoidance

Sun avoidance and clothing are additive to topical sunscreen and recommended as part of any comprehensive photoprotection strategy:

  • Shade-seeking: UV index peaks 10 am–4 pm in temperate latitudes (adjusting for time zone and longitude). Shade under a tree or umbrella reduces direct UV by ~50–75% but scattered/reflected UV persists (reflected UV from sand/water/snow can be 10–80%).
  • UPF clothing: Ultraviolet Protection Factor (UPF) fabric ratings. UPF 50+ transmits <2% UV (analogous to SPF 50). Tightly woven, dark-colored fabrics provide better protection. Wet cotton provides minimal UV protection (UPF ~3). Wide-brimmed hats (>7.5 cm brim) protect face, ears, and neck — areas not reliably covered by sunscreen.
  • UV-protective eyewear: Reduces periocular UV (eyelid squamous cell carcinoma, cataract formation, and periocular photoaging). Broad wraparound frames for full coverage. Look for UV400 designation (blocks UV up to 400 nm, covering UVA-I).
  • Window glass: Standard glass transmits UVA-I (340–400 nm) while blocking UVB and UVA-II. Daily indoor/car exposure to UVA-I is biologically significant for photoaging. UV-blocking window film resolves this for high-exposure windows.

Implementation and dosing

Application thickness: The standard is 2 mg/cm² — the density at which SPF is measured in vitro. Most users apply 0.5–1.0 mg/cm² in practice (i.e., 25–50% of rated dose), which yields approximately SPF²/⁵ of the stated SPF in practice. SPF 50 at 0.5 mg/cm² delivers approximately SPF 7–8 actual protection. A practical heuristic: use more than you think you need.

  • Face + neck + ears: ~0.5 tsp (approximately 1/3 teaspoon, or ~3 finger-lengths per “two-finger rule”)
  • Full body: ~1 oz (30 mL) per application
  • Reapplication: every 2 hours during sun exposure, and immediately after swimming or towelling dry (“water resistant” products are tested at 40 or 80 minutes submersion — not indefinitely)
  • Daily indoor use: Apply once in the morning if not reapplied during the day; primarily for UVA-I window exposure

Timing in skincare routine: Sunscreen is the final step in the morning routine (after moisturizer, serums, and active ingredients). Do NOT apply under a retinoid — retinoid goes on at night; sunscreen goes on in the morning over any morning active ingredients.

Combination with retinoids and antioxidants

UV protection is mandatory for retinoid users. Retinoids (tretinoin, retinol, adapalene, tazarotene) increase photosensitivity by thinning the stratum corneum, increasing keratinocyte turnover, and sensitizing skin to UV-induced AP-1 activation. The original Fisher 1996 mechanism paper 3 used tretinoin as the benchmark antagonist to UV-induced AP-1 activation (70% reduction in AP-1 binding; 50–80% reduction in MMP-1/9 mRNA/protein/activity) — the interpretation being that retinoid use reduces photoaging risk by suppressing MMP induction from UV that penetrates sunscreen. This creates a complementarity: sunscreen limits UV dose; retinoid attenuates the AP-1 response to residual UV.

Antioxidant layering (vitamin C / ascorbic acid + vitamin E / alpha-tocopherol + ferulic acid, applied under sunscreen in the morning) provides additional defense against UV-generated ROS that transmits through sunscreen at sub-SPF-rated wavelengths. Mechanism: ascorbate quenches singlet oxygen and hydroxyl radical; tocopherol intercepts peroxyl radical chain reactions; ferulic acid stabilizes ascorbate photo-oxidation, doubling efficacy of the vitamin C+E combination (Duke 2005, Duke & DiNardo 2012 cited in the antioxidant-serum literature). needs-replication — no RCT has directly tested topical antioxidant layering under sunscreen vs. sunscreen alone for photoaging endpoints.

Commonly combined agents in anti-photoaging protocols:

  • niacinamide — tyrosinase inhibition + anti-inflammatory + skin barrier; often layered under sunscreen
  • ascorbic-acid — morning antioxidant + tyrosinase inhibition
  • alpha-tocopherol — synergistic with ascorbic acid + antioxidant
  • retinoids — PM use mandatory with AM sunscreen

Pregnancy and sensitive-skin considerations

Mineral filters (zinc oxide, titanium dioxide) are generally considered the preferred choice during pregnancy based on the following reasoning: nano-TiO₂ and ZnO show minimal dermal penetration and negligible systemic absorption; no reported hormonal activity. Endocrine-concern filters (oxybenzone, octinoxate, homosalate, octocrylene) have detectable plasma absorption after standard application (FDA 2020 JAMA study) and some in vitro endocrine-disrupting activity — their use in pregnancy is based on precautionary reasoning rather than established fetal harm.

Sensitive skin / rosacea / post-procedure skin: Mineral filters are less likely to sting or irritate inflamed or compromised skin barriers. Chemical filters (avobenzone, oxybenzone) are more prone to contact dermatitis in sensitive individuals.

Oxybenzone and octinoxate are subject to legal restrictions in Hawaii (effective 2021), the Florida Keys, and several Pacific island jurisdictions due to coral reef bleaching concerns. Reef-safe formulations use zinc oxide ± titanium dioxide only.

Evidence gaps and limitations

  1. No lifelong RCT: Hughes 2013 at 4.5 years is the longest controlled study. Cumulative photoprotection over decades has not been tested in an RCT design (decades-long community allocation is not feasible). Lifetime photoaging prevention is extrapolated from the 4.5-year trajectory + mechanistic consistency. long-term-unknown

  2. Visible light and IRA evidence: While the exposome framework 1 5 identifies visible light and IRA as significant contributors, direct clinical evidence that adding VL/IRA protection to standard UV sunscreen reduces photoaging over and above UV-only sunscreen in the general (non-melasma) population is lacking. Iron oxide evidence is primarily for pigmentation endpoints in melasma. needs-replication

  3. Chemical filter systemic safety: FDA 2019/2020 studies show dermal absorption of avobenzone, oxybenzone, octinoxate, octocrylene into plasma above 0.5 ng/mL threshold; long-term chronic-exposure endocrine effects are not established. Precautionary principle drives preference for mineral filters in at-risk populations. long-term-unknown

  4. Application thickness compliance: The 2 mg/cm² standard is rarely achieved in practice. Photoaging-reduction magnitude in real-world use is lower than trial conditions. Studies on behavioral interventions to increase application thickness are limited. dose-response-unclear

  5. Photolyase + DNA repair enzymes: Preliminary signals but no well-powered RCT evidence for superiority over standard UV filters for photoaging reversal or prevention. needs-replication

Cross-organism extrapolation

Not applicable in the conventional sense — UV protection is a human-specific intervention (no model organism uses sunscreen). The underlying biology (UV→CPD→AP-1→MMPs) is mechanistically conserved across mammals. Fisher 1996 established the human in-vivo mechanism directly.

DimensionStatus
Pathway conserved in humans?yes (UV → AP-1 → MMP; directly measured in human skin in vivo)
Phenotype conserved in humans?yes (photoaging is a human clinical endpoint with validated scales)
Replicated in humans?yes (Hughes 2013 RCT; Rönsch 2021 systematic review)

Cross-references

  • skin-aging — the primary phenotype target
  • krutmann-2017-skin-aging-exposome — R39-verified anchor review (exposome framework; sunscreen best-evidenced intervention)
  • fisher-1996-photoaging-ap1-mmp — R39-verified mechanistic anchor (sub-erythemogenic UVB → AP-1/NF-κB → MMP cascade)
  • epidermis — primary UV-target tissue layer
  • keratinocytes — cells bearing the UV-induced AP-1 and NF-κB response
  • melanocytes — pigmentation response to UV; visible-light driven melanogenesis
  • melanogenesis — pathway activated by UV + visible light
  • retinoids — mandatory companion; increases photosensitivity; shared AP-1-transrepression mechanism
  • ascorbic-acid — morning antioxidant layer; UV-ROS scavenging; tyrosinase inhibition
  • alpha-tocopherol — synergistic antioxidant co-deployed with ascorbic acid
  • niacinamide — anti-inflammatory + tyrosinase-inhibitor adjunct
  • genomic-instability — hallmark; UV-induced CPD/6-4PPs drive DNA damage burden
  • loss-of-proteostasis — hallmark; UV-MMP cascade degrades dermal collagen/elastin
  • chronic-inflammation — hallmark; UV-NF-κB drives cytokine induction; tanning-response inflammation
  • ap-1-pathway — proximal transcription factor target (AP-1 = c-Jun/c-Fos complex)
  • nf-kb — co-activated with AP-1 by UV in epidermis

Footnotes

Footnotes

  1. krutmann-2017-skin-aging-exposome · n=null (review) · review · model: human skin aging · doi:10.1016/j.jdermsci.2016.09.015 · R39-verified (2026-05-19) · defines UV as dominant extrinsic photoaging driver; cites Hughes 2013 for sunscreen RCT; proposes skin aging exposome framework including visible light + IRA + pollution ↩ ↩2 ↩3

  2. doi:10.7326/0003-4819-158-11-201306040-00002 · Hughes MCB, Williams GM, Baker P, Green AC · Ann Intern Med 2013;158(11):781–790 · PMID: 23732711 · rct (2×2 factorial; 4 arms: daily sunscreen ± beta-carotene vs. discretionary sunscreen ± beta-carotene) · n=903 (Australian adults ≤55 yr; mean age 39 yr; Queensland) · 4.5-year trial (1992–1996); daily SPF 15+ broad-spectrum sunscreen vs discretionary use; skin microtopography of dermal elastosis on dorsal hands by silicone cast + profilometry · visible skin aging 24% less in daily sunscreen group vs discretionary use (relative odds 0.76; 95% CI 0.59–0.98); beta-carotene no overall benefit · archive: confirmed DOI in a local paper archive; closed-access; not downloaded (FWCI 19.6; citation_percentile 100th) ↩ ↩2

  3. fisher-1996-photoaging-ap1-mmp · n=6–17 (varies per experiment) · in-vivo · model: human buttock skin · doi:10.1038/379335a0 · R39-verified (2026-05-19) · 0.01 MED UVB activates AP-1 and NF-κB within minutes; drives MMP-1, MMP-3, MMP-9 in human skin in vivo; tretinoin reduces AP-1 binding 70% + MMP-1/9 mRNA/protein/activity 50–80% ↩ ↩2 ↩3

  4. doi:10.1016/j.jaad.2020.04.079 · Lyons AB, Trullas C, Kohli I, Hamzavi IH, Lim HW · J Am Acad Dermatol 2021;84(5):1393–1397 · review · iron oxides + pigmentary TiO₂ in tinted sunscreens provide visible-light (400–700 nm) protection; clinical applications: melasma, post-inflammatory hyperpigmentation, photodermatoses · archive: confirmed DOI; closed-access; not downloaded (FWCI 19.6; 179 citations) · no-fulltext-access — claims unverified against full PDF ↩

  5. doi:10.1111/phpp.12688 · Krutmann J, Schalka S, Watson REB, Wei L, Morita A · Photodermatol Photoimmunol Photomed 2021;37(5):401–411 · PMID: 33896049 · review · model: human · recommends SPF ≥30 with high UVA-PF; argues for antioxidant-containing formulations for IRA/pollution protection; iron oxides for visible-light protection primarily for melasma prevention and actinic lentigo; notes sunscreen is generally under-applied at ~25% of recommended dose in practice; no conclusive safety concerns for daily sunscreen use · archive: confirmed DOI; hybrid OA; downloaded (FWCI 17.1; 78 citations) ↩ ↩2 ↩3

  6. doi:10.1016/j.xjidi.2021.100070 · Marionnet C, Tricaud C, Stocker L, et al. · JID Innov 2022;2(1):100070 · in-vitro RHE + in-vivo intra-individual RCT (NCT04865094) · n=19, Fitzpatrick III–IV · MCE λmax 385 nm; MW 322.41 g/mol; ε≈63,052 M⁻¹cm⁻¹ (ethanol); MCE-enriched SPF formula reduced UVA1-induced fibroblast loss, MMP1/IL-1RA/IL-6/IL-8/GM-CSF release, and 27+24 gene-expression dysregulations vs SPF50 base alone; PPD ΔL* attenuated · COI: all L’Oréal ↩

  7. doi:10.1111/jdv.19486 · Flament F, Bourokba N, Nouveau S, et al. · J Eur Acad Dermatol Venereol 2024;38(1):214–222 · rct (intra-individual, outdoor, 8 wk) · n=113 women (Brazil + China, phototype III–V) · SPF50 + 3% MCE vs same SPF50 minus MCE; smaller pigmentation increase + better skin-aging severity scores on MCE side · COI: all L’Oréal/La Roche-Posay ↩

  8. doi:10.1111/phpp.13020 · Mercurio DG, Wagemaker TAL, Passeron T, et al. · Photodermatol Photoimmunol Photomed 2025;41(1):e13020 · rct (intra-individual, outdoor, 4 wk) · n=52 Brazilian women (phototype I–III) · SPF50 + 1% MCE vs SPF50 base; expert-panel superiority of MCE side on upper-lip wrinkles, crow’s feet, pigmentation endpoints (all p<0.0001) · COI: all L’Oréal · no-fulltext-access ↩

  9. doi:10.1111/cod.14700 · Loretan C, Piletta P, Rossel JB · Contact Dermatitis 2024;92(1):80–81 · case report · n=1 + 12 atopic controls · 59-yo woman, 1 yr facial dermatitis traced to UVMune 400; ++ patch test to MCE 1%; controls negative · first independent (non-L’Oréal) MCE human publication ↩

  10. doi:10.1111/jdv.19290 · Boyer F, Cieslik C, Brugnara L, et al. · J Eur Acad Dermatol Venereol 2023;37 Suppl 6:12–21 · two open intra-individual hemi-back RCTs · n=20 + n=16 women · 412 nm 50 J/cm² blue-light challenge; TriAsorB-containing SPF50+ reduced BL-induced immediate pigmentation 50.7–75.5% colorimetric (p<0.001), 31.2–72.7% visual scoring · COI: Pierre Fabre; sponsor supplement issue; not blinded ↩

  11. doi:10.1111/jdv.19243 · Le Digabel J, Cieslik C, Borel M, et al. · J Eur Acad Dermatol Venereol 2023;37 Suppl 6:6–11 · in-vivo multispectral reflectance · TriAsorB product significantly higher 380–450 nm absorbance vs 5 SPF50+ commercial comparators (comparators not named) · COI: Pierre Fabre ↩

  12. doi:10.1007/s11356-025-36772-y · Fagervold SK, et al. · Environ Sci Pollut Res Int 2025;32(33):19823–19835 · marine sediment microcosms · TriAsorB not biodegraded after 100 d (along with most modern triazine filters); BP3/homosalate/octisalate were degraded · COI: Pierre Fabre co-funded · environmental-persistence finding ↩

  13. doi:10.1001/jama.2019.5586 · Matta MK, Zusterzeel R, Pilli NR, et al. (FDA Office of Clinical Pharmacology) · JAMA 2019;321(21):2082–2091 · rct (open-label maximal-use PK) · n=24 healthy adults · 2 mg/cm² × 4 applications/day × 4 days; lotion, aerosol spray, non-aerosol spray formulations · all four tested filters (avobenzone, oxybenzone, octocrylene, ecamsule) exceeded 0.5 ng/mL plasma threshold within 4 hr of first application; Cmax: oxybenzone 209.6 ng/mL; avobenzone 4.0–8.7 ng/mL; octocrylene 4.5–7.8 ng/mL; ecamsule 1.5 ng/mL · no-fulltext-access — abstract-level ↩ ↩2 ↩3 ↩4

  14. doi:10.1001/jama.2019.20747 · Matta MK, Florian J, Zusterzeel R, et al. (FDA) · JAMA 2020;323(3):256–267 · rct · n=48 healthy adults · expanded panel: avobenzone, oxybenzone, octocrylene, homosalate (Cmax 23.1 ng/mL), octisalate (5.1 ng/mL), octinoxate (7.9 ng/mL); all 6 filters exceeded 0.5 ng/mL by single-day maximal-use application; persistence through day 21 documented for several filters · no-fulltext-access — abstract-level ↩ ↩2 ↩3

  15. doi:10.1159/000517641 · Rönsch H, Bauer A · Curr Probl Dermatol 2021;55:166–181 · systematic-review · 5 trials (28–1,621 participants) · significant AK reduction (all 4 studies); significant SCC reduction (2 studies); significant photoaging reduction in sunscreen groups; non-significant BCC trend · archive: confirmed DOI; closed-access; not downloaded (FWCI 8.7) · no-fulltext-access — quantitative claims for this footnote unverified against full PDF; primary result framing sourced from seeder extraction ↩

  16. doi:10.1016/j.abd.2021.06.005 · Alvares BA, Miola AC, Schimitt JV, Miot HA, Abbade LPF · An Bras Dermatol 2022;97(2):157–165 · rct (2×2 factorial, double-blind for antioxidant arm) · n=40 participants (80 forearms); aged 60–90 yr; AK on forearms · 8-week; SPF 99 sunscreen ± photolyase (both forearms) + topical AOx (15% L-ascorbic acid + 1% alpha-tocopherol + 0.5% ferulic acid) vs. placebo (one forearm each, nocturnal) · AOx significantly reduced AK count (22%, p<0.05) vs placebo; partial clearance 47.4% AOx vs 23.7% placebo (p=0.018); no significant difference between photolyase-containing and regular sunscreen on any outcome · archive: confirmed DOI; gold OA; downloaded (FWCI 6.7) ↩

  17. doi:10.1111/phpp.12597 · Luze H, Nischwitz SP, Zalaudek I, Müllegger R, Kamolz LP · Photodermatol Photoimmunol Photomed 2020;36:424–432 · systematic-review (PubMed + Web of Science; NOS>5 quality threshold) · 52 relevant studies from 352 publications (31 in vivo, 14 in vitro/ex vivo, 7 animal, 10 reviews used for background only) · DNA repair enzymes (photolyase and T4 endonuclease V) in sunscreens can enhance CPD/6-4PP repair mechanisms; however: “There is a lack of randomized controlled trials demonstrating the efficacy of DNA repair enzymes on photoageing, or a superiority of sunscreens with DNA repair enzymes compared to conventional sunscreens.” · archive: confirmed DOI; hybrid OA; downloaded (FWCI 3.8) ↩

Graph View

Backlinks